
    
      This study is a randomized, double-blind, single dose design. This study is conducted in male
      and female patients between ≥40 and 85 years of age with severe osteoarthritis of the knee.
      Approximately 1034 patients with severe osteoarthritis of the knee randomized 1 to 1
      treatment group (1:1) will receive a single intra- injection of 4 milliliter (mL) of Ampion
      or saline.

      The clinical effects of treatment on severe osteoarthritis of the knee will be evaluated at
      baseline and at 2, 4, 6, 8, 10, 12, and 24 weeks, using the Western Ontario and McMaster
      Universities Arthritis Index (WOMAC®) osteoarthritis Index 3.1, and the Patient's Global
      Assessment of disease severity (PGA).
    
  